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Available online 19 April 2017Introduction: In South Africa’s high injury prevalent setting, it is imperative that injury mortality is kept
to a minimum. The CRASH-2 trial showed that Tranexamic acid (TXA) in severe injury reduces mortality.
Implementation of this into injury protocols has been slow despite the evidence. The 2013 Western Cape
Emergency Medicine Guidelines adopted the use of TXA. This study aims to describe compliance.
Methods: A retrospective study of TXA use in adult injury patients presenting to Khayelitsha Hospital was
done. A sample of 301 patients was randomly selected from Khayelitsha’s resuscitation database and data
were supplemented through chart review. The primary endpoint was compliance with local guidance:
systolic blood pressure <90 or heart rate >110 or a significant risk of haemorrhage. Injury Severity
Score (ISS) was used as a proxy for the latter. ISS >16 was interpreted as high risk of haemorrhage and
ISS <8 as low risk. Linear regression and Fischer’s Exact test were used to explore assumptions.
Results: Overall compliance was 58% (172 of 295). For those without an indication, this was 96% (172 of
180). Of the 115 patients who had an indication, only eight (18%) received the first dose of TXA and none
received a follow-up infusion. Compliance with the protocol was significantly better if an indication for
TXA did not exist, compared to when one did (p < 0.001). Increased TXA use was associated only with ISS
>15 (p < 0.001).
Discussion: TXA is not used in accordance with local guidelines. It was as likely not to be used when indi-
cated than when not indicated. Reasons for this are multifactorial and likely include stock levels, lack of
administration equipment, time to reach definitive care, poor documentation and hesitancy to use.
Further investigation is needed to understand the barriers to administration.
 2017 African Federation for Emergency Medicine. Publishing services provided by Elsevier B.V. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
a b s t r a c t
Introduction: Dans l’environnement sud-africain caractérisé par une forte prévalence de blessures, il est
impératif que la mortalité liée aux blessures soit maintenue à un minimum. L’essai CRASH-2 a indiqué
que l’acide tranexamique (ATX) réduisait la mortalité en cas de blessures graves. L’adoption de cette
procédure dans les protocoles de gestion des blessures a été lente, en dépit des données probantes. Les
Directives de médecine d’urgence du Cap occidental 2013 ont adopté l’utilisation de l’ATX. L’étude vise
à décrire la conformité.
Méthodes: Une étude rétrospective de l’utilisation de l’ATX chez les patients adultes souffrant de blessu-
res et se présentant à l’hôpital de Khayelitsha a été réalisée. Un échantillon de 301 patients a été sélec-
tionné de manière aléatoire dans la base de données de réanimation de Khayelitsha et les données ont été
complétées par un examen des dossiers. Le principal paramètre était la conformité aux directives locales:
une tension artérielle systolique <90, un rythme cardiaque >110 ou un risque d’hémorragie significatif.
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été interprété comme un fort risque d’hémorragie et un IGB <8 comme un faible risque. La régression
linéraire et la méthode exacte de Fisher ont été utilisées afin d’étudier les hypothèses.
Résultats: Le taux de conformité générale s’élevait à 58% (172 sur 295). Pour ceux ne présentant aucune
indication, ce taux s’élevait à 96% (172 sur 180). Sur les 115 patients présentant une indication, seule-
ment huit (18%) avaient reçu la première dose d’ATX et aucun n’avait reçu d’injection subséquente. Le
respect du protocole était considérablement meilleur si aucune indication d’ATX n’existait, par rapport
à son existence (p < 0,001). Une augmentation de l’utilisation de l’ATX n’était associée qu’à un IGB> 15
(p < 0,001).
Discussion: L’ATX n’est pas utilisé conformément aux directives locales. Il était tout aussi susceptible de
ne pas être utilisé lorsque cela était indiqué que lorsque cela ne l’était pas. Les raisons en sont multiples et
incluent probablement la disponibilité en stock, le manque de matériel d’administration, le temps pour
atteindre le lieu de prise en charge définitif, l’absence de documentation et l’hésitation à l’utiliser. Des
enquêtes supplémentaires sont nécessaires pour comprendre les barrières à l’administration.
 2017 African Federation for Emergency Medicine. Publishing services provided by Elsevier B.V. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).African relevance
 Low- and middle-income countries are heavily burdened by
morbidity and mortality caused by trauma.
 Tranexamic acid has been shown to reduce trauma-related
mortality.
 This study shows that Tranexamic acid is not administered
appropriately when indicated.
Introduction
Globally low- and middle-income regions are burdened by mor-
bidity and mortality due to serious injury [1]. South Africa is no
exception, however, matters related to injury morbidity and mor-
tality locally have been largely unexplored. The National Burden
of Disease study by Bradshaw, et al. in 2000 found that injuries
were South Africa’s third leading cause of death (or 12% of all
deaths) [2]. Little has changed since then; Statistics South Africa
reported in 2013 that injuries contributed to 10% of all deaths –
much higher than what would be expected in a high-income coun-
try [3]. Unsurprisingly, injury burden at emergency centres (EC)
are high. In Cape Town, South Africa’s second largest city, as much
as 36% of adult presentations are injury related [4].
Coagulopathy, hypothermia and acidosis are considered the
three key mechanisms whereby injury leads to death [5]. Coagu-
lopathy has been of particular interest recently due to the
CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Signifi-
cant Haemorrhage) findings and its recommendation of Tranex-
amic acid (TXA) use for serious injury [6]. TXA is a synthetic
derivative of the amino-acid lysine. It works as an antifibrinolytic
agent by binding to plasminogen and blocking the interaction of
plasminogen with fibrin, thus preventing lysis of the fibrin clot
[7]. In 2010, the CRASH-2 trial provided good evidence that TXA
in severely injured patients saves lives, with a relative risk reduc-
tion of close to 10% in all-cause mortality, and 15% in haemorrhage
related mortality [6]. In the study, injured, adult patients were ran-
domised to receive TXA if they had a systolic blood pressure (SBP)
less than 90 mmHg, a heart rate (HR) greater than 110 and/or were
at a high risk of significant bleeding. Administration within three
hours of the injury showed the largest benefit [6].
The CRASH-2 trial recruited 20,211 patients from 274 hospitals
in 40 countries. Of particular interest was that a significant number
of participants were drawn from low- and middle-income regions
including South Africa. It was the largest ever injury-related, ran-
domised control trial in history and its findings have largely been
accepted as fairly robust [6]. The Military Application of TXA in
Injury Resuscitation study subsequently confirmed CRASH-20s
findings in a more severely-injured, military sample; it found that
TXA administration resulted in more than 6% absolute reduction inmortality compared to controls, despite higher Injury Severity
Scores in the TXA-arm [8].
Paradoxically, the uptake of TXA recommendations in global,
clinical injury guidelines has been rather slow. For example, the
2012 version of the Advanced Injury Life Support guidance did
not include TXA [9]. Using data from the World Health Organisa-
tion and the CRASH-2 findings, it was shown that 1189 additional
lives could be saved annually in South Africa if TXA was adminis-
tered within three hours [10]. It was for this reason that the Wes-
tern Cape Emergency Care guidelines (South Africa) included TXA
use for serious trauma in its 2013 guidelines, and is stocked in
all local ECs [11]. The aim of this audit was to review the appropri-
ateness of TXA use at a single district, public hospital’s EC using the
provincial guidelines as a reference standard.
Methods
Data were obtained through a retrospective analysis of an exist-
ing database and supplemented through a retrospective chart
review. The audit received ethical approval from the human
research ethics committee, University of Cape Town. It was con-
ducted at the EC of Khayelitsha hospital – a district, public hospital
on the outskirts of Cape Town. Khayelitsha hospital is a 240-bed
hospital with a 24-h EC. Its workforce consists of emergency med-
icine consultants, permanent medical officers, community service
medical officers and emergency medicine specialist trainees. The
suburb of Khayelitsha houses around 400,000 people, of which
55% live in informal settlements and 74% earn a monthly income
of USD 220 or less [12].
The database used for primary data collection was established
during the month of November 2014. This database captures vari-
ous clinical variables via a smartphone application on all patients
managed within the resuscitation area of Khayelitsha hospital EC.
All patients older than 13-years, who presented with an injury dur-
ing twelve, randomly selected weeks (randomised using Excel:
Microsoft Office, 2016, Redmond, USA) were extracted from this
database. A nursing register of patients treated in the resuscitation
area was crosschecked to ensure all patients over the selected data
collection periods were included. Any missing data were captured
through subsequent chart review. Key variables collected included
time of arrival, age, SBP and HR at triage, detailed list of injuries,
administration of TXA and method of administration. The Abbrevi-
ated Injury Score (AIS) was derived from injury variables, and used
to calculate the Injury Severity Score (ISS) for each subject. Patients
with partially missing data were included for analysis except
where analyses involved the specific missing variable.
The main outcome measure was appropriate use of TXA, depen-
dant on the presence or absence of one or more of the three indi-
cations for TXA use: SBP  90 mmHg, HR  110, and patients
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sible to retrospectively quantify a significant risk of haemorrhage
objectively, we decided a priori, to assess the risk of haemorrhage
by using the ISS (a measure of severity) as a subjective measure
of risk of haemorrhage. The ISS has previously been associated with
a need for blood products [5,13]. Patients with an ISS 8 (low
severity) were deemed at low risk of haemorrhage, whilst patients
with an ISS 16 (high severity) were deemed at significant risk of
haemorrhage. For the purposes of this audit, an ISS ranging from 9
to 15 (moderate severity) was deemed appropriate whether TXA
was used or not. Appropriate TXA use was defined as documented
administration of 1 g TXA over ten minutes followed by 1 g given
over eight hours. Microsoft Excel was used for analysis. Summary
statistics were used to describe all collected variables, including
48-h and 7-day mortality. Overall, compliance with the protocol
was calculated for each of the three TXA indications and expressed
as proportions. Associations between the indications and TXA
administration were tested using linear regression and the Fisher
Exact test (STATA: Statacorp, 2015, Texas, USA).Results
The database yielded 301 injured patients of which six had to be
excluded; three patients were incorrectly classified as injured; twoFig. 1. Audit findings of appropriate TXA use. TXA, Tranexamic acid; *, Includes four patie
followed by 1 g over eight hours.patients lacked all required variables and one patient absconded
prior to being seen. For the remaining 295 patients, 207 (70%) pre-
sented between the hours 20:00 and 08:00; of which 159 (77%)
presented between the hours 20:00 and 04:00. The sample con-
sisted of 87% (258/295) male patients. The median values for the
remaining variables were: age 27 years (inter-quartile range
(IQR) 23–34), HR 92 beats per minute (IQR 80–107), SBP
123 mmHg (IQR 108–140) and ISS 5 (IQR 4–10). Three further
patients were excluded from compliance calculations for individ-
ual indications as the injury severity was not captured.
Fig. 1 describes the audit’s main findings. Overall compliance to
the TXA guideline was 58% (172/295). Of the 115 patients who had
one or a combination of indications, 21 (18%) received a first dose
of TXA. Of the 21 patients who received a correct, first dose of TXA,
none received the follow-on infusion. Of the 180 patients who did
not have an indication, 172 (96%) did not receive TXA. Tranexamic
acid was used significantly more appropriately if an indication did
not exist, compared to when one did (p < 0.001).
Patients presenting with HR > 109, were less likely to receive
TXA (6%, 3 of 50) when compared to SBP < 90 (26.7%, 4 of 15)
and ISS >15 (20%, 5 of 25) although this difference was not statis-
tically significant (p = 0.08). Linear regression analysis of these
subgroups showed that only an ISS >15 was significantly associ-
ated with appropriate TXA administration (p < 0.001). When subdi-
viding the sample according to ISS, those with an ISS >15 werents with only Injury Severity Scores between 9 and 15 that received TXA; y, 1 g stat
Table 1
Compliance for individual indications (n = 292).
Indication Patients with indication
n (%)
Correctly received TXA
n (%)
HR only 50 (17) 3 (6)
HR and SBP 2 (1) 0
HR and ISS 10 (3) 4 (40)
All patients with HR 63 (22) 7 (11)
SBP only 15 (5) 4 (27)
SBP and ISS 7 (2) 0
All patients with SBP 25 (9) 4 (16)
Only ISS 25 (9) 5 (20)
All patients with ISS 42 (14) 9 (21)
HR, SBP and ISS 1 (0) 0
HR, heart rate; SBP, systolic blood pressure; ISS, Injury Severity Score; TXA,
Tranexamic acid.
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between 9 and 15 (6.2%, 4 of 65) and ISS <9 (6.8%, 8 of 117)
although this difference was not statistically significant
(p = 0.17). The 48-h and 7-day mortality were similar, 1.4% (4 of
295). Table 1 presents the patients who appropriately received
the first TXA dose. Not a single patient received the follow-on dose.
Of the 42 patients with ISS 16 as an indication for TXA, nine had
head injuries that contributed significantly to the calculation of the
ISS. One of these received TXA.Discussion
Tranexamic acid was not appropriately administered for a sig-
nificant number of patients who were likely to have indications
for use. This was mainly due to TXA not being given for the indica-
tions outlined in the local clinical guidelines. Where it was given,
only the first dose was given, but no follow-on infusion. The find-
ings suggest that TXA was either not stocked for use, patients took
too long to reach the hospital, clinicians were hesitant to use it or
clinicians did use it, but simply failed to document this. It was
beyond the remit of the retrospective design to correct the findings
for stock-levels of TXA at the time of the patient’s treatment.
Although possible, it seems unlikely that TXA could have been
out-of-stock for such a large proportion of the data collection per-
iod. The time taken to reach hospital could be a possible reason for
the poor adherence; although the EC is situated in an urban area
close to a city ambulance base it serves a reasonably sized area,
with challenging access as well as a number of primary care refer-
ral centres. Anecdotally, delays are commonly experienced. Lack of
resources, such as an infusion pump, may have contributed to the
lack of administration of the follow-on dose. Although all of these
reasons would have influenced TXA use, it would seem unusual to
have been the cause of non-usage so often over the data collection
period. Unfortunately, there are no data to support any of these
assumptions.
The audit suggests a certain degree of hesitancy to TXA’s use.
The difference between the Western Cape and Advanced Trauma
Life Support guidelines might have contributed to this hesitancy
[9,11]. Although disappointing, these results are in keeping with
TXA use for injury reported elsewhere. A 2015 review, assessing
compliance of the 2013 European injury guidelines (that also
include TXA use for the CRASH-2 indications) revealed that only
66% of respondents used TXA [14]. And in a tertiary American cen-
tre, only 38% of eligible patients received TXA after it was specifi-
cally implemented as part of a massive transfusion protocol [15].
Given that Khayelitsha Hospital’s EC forms part of a training net-
work for emergency specialist trainees who rotate through another
seven emergency medicine specialist-run ECs around the city ofCape Town, it is important to establish whether the findings of this
audit are a city-wide phenomenon.
The mortality in this audit was low. This should however, not be
seen as a reason why TXA could be omitted. As stated previously,
the benefit is of a relative reduction of mortality of around 10%
[6]. This means that for every ten injured patients that died not
receiving TXA, only nine would have died had they received it. It
follows that the impact will be greater if calculated over a longer
time and/or citywide. It has to be borne in mind that this study
represents the findings of an audit aimed at service improvement.
The findings likely reveal the potential for further research to opti-
mise this aspect of trauma care throughout all the city’s public ECs.
Abnormal vital signs were significantly less associated with TXA
use compared to severe injury as per an ISS >15. Whereas vital
signs are objective measures of severity, estimating the risk of
severity (and thereby the risk of haemorrhage) is fairly subjective.
One of the limitations of this audit was the inability to objectively
evaluate the retrospective risk of haemorrhage. Given the associa-
tion between ISS and haemorrhage, this proxy use of ISS provided a
reasonable solution to estimating the risk retrospectively [5,13]. It
is important to note, however, that ISS was only calculated for the
purposes of this retrospective study. We are not suggesting in any
way to incorporate ISS into the protocol of TXA use. Another limi-
tation regarded the small sample – the size renders it impossible to
make generalisations of TXA administration for both an extended
time interval and TXA use in other public ECs in the region. It
would however be disingenuous to disregard the findings, seeing
that in all likelihood it suggests a citywide shortfall in injury care.
A useful addition to future audits would be time from injury to EC.
Although originally included in the proposal, poor record keeping
excluded the inclusion of a time variable. Future studies should
either be prospective or care needs to be taken to select a retro-
spective sample that includes this variable. Finally, the use of blood
products was not recorded. However, since the use of blood prod-
ucts is commonly used as a prompt for TXA use, future audits
should include the use of blood products alongside an evaluation
of TXA use.
The mortality benefit of appropriate TXA use is fairly certain
and as previously stated has been estimated to substantially
reduce mortality due to injury locally [10]. When considering
the relatively low cost of TXA compared to other modalities of
injury care (i.e. imaging and blood products), it seems imprudent
to ignore the findings of this small audit. These suggest barriers
to TXA use. The Western Cape Guidelines have taken a step in
the right direction including the CRASH-2 findings in the local
guideline. This audit has shown that there is likely to be room
for improvement regarding TXA use for severely injured patients.
Further research is now needed to explore the barriers sug-
gested. Stock levels and administration equipment should be rel-
atively straight forward to address. Substantial prehospital
delays to definitive care might suggest that the initial TXA dose
be licensed for use by appropriate prehospital providers, as is
done elsewhere [16]. Improved record keeping would also go a
long way to improve data capture and thus quality of retrospec-
tive research. Although currently lacking, an injury surveillance
registry will allow clinicians to track quality metrics such as
TXA use in order to drive quality of care and evidence-based
practice.Conflicts of interest
Stevan Bruijns is an editor for the African Journal of Emergency
Medicine. All peer reviews are performed blinded and the author
was not involved with the editing of this paper. The authors
declare no further conflict of interest.
J.G.G. Wiese et al. / African Journal of Emergency Medicine 7 (2017) 63–67 67Dissemination of findings
SL disseminated findings to the staff at the study site. Results
were presented as a poster at the African Conference for Emer-
gency Medicine in Cairo, 2016.
Author contribution
DH and SB conceived the original idea of the study. LH con-
structed and maintained the database from which the sample
was drawn. SL assisted with the implementation of and mainte-
nance of the database. JW did the data collection and analysis.
JW drafted the manuscript with input from SB and DH. SB,DH
and SL revised the manuscript. JW, LH, SB,DH and SL approved
the final version that was submitted.
References
[1] Gosselin R. Injuries: the neglected burden in developing countries. Bull World
Health Organ 2009;87(4).
[2] Bradshaw D, Groenewald P, Laubscher R, et al. Initial burden of disease
estimates for South Africa. SAMJ South African Med J 2003;93(9):682–8.
Health and Medical Publishing Group.
[3] Statistics South Africa. Mortality and Causes of death in South Africa, 2013:
Findings from death Notification. Pretoria; 2013.
[4] Wallis LA, Twomey M. Workload and casemix in Cape Town emergency
departments. South African Med J 2007;97(12 I):1276–80.
[5] Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma
2003;54(6):1127–30.[6] Williams-Johnson JA, McDonald AH, Strachan GG, et al. Effects of tranexamic
acid on death, vascular occlusive events, and blood transfusion in trauma
patients with significant haemorrhage (CRASH-2) a randomised, placebo-
controlled trial. West Indian Med J 2010;59(6):612–24.
[7] Pfizer. Cyklokapron (tranexamic acid injection): US prescribing information.)
Available from: http://labeling.pfizer.com/showlabeling.aspx?id=556 (Last
accessed 18 November 2016.
[8] Ghazi S, Pierson R, Torlinski T. Military application of tranexamic acid in
trauma emergency resuscitation study 2C03, 3C00. J Intensive Care Soc
2013:86–8.
[9] American College of Surgeons. Advanced Trauma Life Support (ATLS) Student
Course Manual. Chicago, IL: American College of Surgeons; 2012.
[10] Guerriero C, Cairns J, Perel P, et al. Cost-effectiveness analysis of administering
tranexamic acid to bleeding trauma patients using evidence from the CRASH-2
trial. PLoS One [Internet] 2011;6(5):e18987. Available from: http://www.ncbi.
nlm.nih.gov/pubmed/21559279.
[11] Ackernan S, Blockman M, Botha P, et al. Emergency Medicine Guidance. 3rd ed.
Welzel T, editor. Division of Emergency Medicine, US & UCT; 2013.
[12] Statistics South Africa. City of Cape Town – 2011 Census Suburb Khayelitsha.
2011.
[13] Malone DL, Dunne J, Tracy JK, et al. Blood transfusion, independent of shock
severity, is associated with worse outcome in trauma. J Trauma 2003;54
(5):898–905 [905-7].
[14] Hamada SR, Gauss T, Pann J, et al. European trauma guideline compliance
assessment: the ETRAUSS study. Crit Care [Internet]. 2015 [cited 2016 Jul
22];19:423. Available from: http://www.pubmedcentral.nih.gov/articlerender.
fcgi?artid=4672560&tool=pmcentrez&rendertype=abstract.
[15] Farrell MN, Wing AH, Burke AP, et al. Addition of tranexamic acid to a
traumatic injury massive transfusion protocol. Am J Heal Pharm. 2015;72
(12):1059–64.
[16] Fischer PE, Bulger EM, Perina DG, et al. Guidance Document for the Prehospital
Use of Tranexamic Acid in Injured Patients. Prehosp Emerg Care 2016;1–3.
